Feasibility Study to Evaluate Renal Denervation Using Focused Ultrasound

This study is a prospective, multi-center trial wherein each included subject will receive the experimental externally focused ultrasound renal denervation therapy. It will be conducted on a maximum of fifty patients who meet the inclusion and exclusion criteria and have signed the informed consent form. Safety is the primary endpoint of this study and will be assessed by incidence and evaluation of any serious adverse effects associated with the investigational procedure through the 52-week evaluation. Clinical utility is the secondary endpoint of this study and will be evaluated by assessing pre and post therapy systolic and diastolic blood pressure.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Monash Medical Center, Melbourne, Australia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subject is at least 18 years of age.
Subject has systolic blood pressure of 160 mmHg in average or greater.
Subject has refractory, stable hypertension despite being treated with at least three hypertensive drugs.
Subject has two functioning kidneys, defined as eGFR ≥ 45 ml/min.
Subject has at least one renal artery on each side which is greater than 4mm.

Exclusion criteria

Subject has hydronephrosis as seen on MRA or ultrasound.
Subject has renal stenosis greater than 50% based on baseline MRA.
Subject has a renal stent or other implant in the region.
Subject has kidney stones which are symptomatic and/or greater than 1cm or in the discretion of the investigator may interfere with treatment.
Subject has a history of abdominal surgery within the past six months.
Subject has heterogeneities in the kidney such as large cysts or tumors which in the discretion of the investigator may interfere with treatment.
Subject has active pyelonephritis or a history of pyelonephritis which in the discretion of the investigator may interfere with treatment.
Subject has a history of myocardial infarction, unstable angina pectoris, or cerebrovascular accident within the last six months.
Subject has hemodynamically significant valvular heart disease.
Subject has an implantable cardioverter defibrillator, pacemaker, neurostimulator or other device incompatible with MRI.
Subject has a body weight > 150 kilograms.
Subject has a target treatment depth > 14 cm.
Subject is pregnant, nursing or intends to become pregnant during the trial period.
Subject is currently enrolled in other potentially confounding research.
Subject has any condition that, at the discretion of the investigator, would preclude participation in the trial.

Treatment and study plan

Kona Externally Focused Ultrasound Therapy

Device

Primary outcomes

Safety: Incidence of Adverse Events through 52 week follow-up

Time frame: One Year

Safety will be assessed by incidence and evaluation of any serious adverse effects associated with the investigational procedure through the 52-week evaluation of bilateral treatment. Included in this assessment will be the proportion of subjects with any of the following outcomes: (1) death, or (2) medical morbidity, including but not limited to renal artery aneurysm, stenosis, significant deterioration of renal function, fistulae or ureteral stenosis.

Secondary outcomes

Decrease in Blood Pressure

Time frame: 12 and 24 weeks post therapy

Clinical utility will be evaluated by assessing pre and post therapy systolic and diastolic blood pressure.

Sponsors and collaborators

Lead sponsor

Kona Medical Inc.

Industry

Registry information

Official study title

A Feasibility Study: An Evaluation of Renal Denervation Using Externally Focused Therapeutic Ultrasound on Patients With Refractory Hypertension

Important dates

Study start: 2012
Primary completion: 2014
Study completion: 2014
First posted: Oct 11, 2012
Registry last updated: Apr 13, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed